Natera Inc
NASDAQ:NTRA
Intrinsic Value
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. [ Read More ]
The intrinsic value of one NTRA stock under the Base Case scenario is 94.61 USD. Compared to the current market price of 103.71 USD, Natera Inc is Overvalued by 9%.
Valuation Backtest
Natera Inc
Run backtest to discover the historical profit from buying and selling NTRA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Natera Inc
Current Assets | 1.3B |
Cash & Short-Term Investments | 882.9m |
Receivables | 288.7m |
Other Current Assets | 89.8m |
Non-Current Assets | 206.8m |
PP&E | 180.3m |
Other Non-Current Assets | 26.4m |
Current Liabilities | 305.9m |
Accounts Payable | 26m |
Accrued Liabilities | 163.8m |
Short-Term Debt | 80.4m |
Other Current Liabilities | 35.7m |
Non-Current Liabilities | 368.1m |
Long-Term Debt | 283.3m |
Other Non-Current Liabilities | 84.9m |
Earnings Waterfall
Natera Inc
Revenue
|
1.2B
USD
|
Cost of Revenue
|
-600.8m
USD
|
Gross Profit
|
607.8m
USD
|
Operating Expenses
|
-990m
USD
|
Operating Income
|
-382.3m
USD
|
Other Expenses
|
16.8m
USD
|
Net Income
|
-365.4m
USD
|
Free Cash Flow Analysis
Natera Inc
NTRA Profitability Score
Profitability Due Diligence
Natera Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Natera Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
NTRA Solvency Score
Solvency Due Diligence
Natera Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Natera Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NTRA Price Targets Summary
Natera Inc
According to Wall Street analysts, the average 1-year price target for NTRA is 106.02 USD with a low forecast of 37.37 USD and a high forecast of 141.75 USD.
Ownership
NTRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NTRA Price
Natera Inc
Average Annual Return | 45.92% |
Standard Deviation of Annual Returns | 106.57% |
Max Drawdown | -78% |
Market Capitalization | 12.7B USD |
Shares Outstanding | 122 242 000 |
Percentage of Shares Shorted | 5.3% |
NTRA News
Last Important Events
Natera Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Natera Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 2,670 full-time employees. The company went IPO on 2015-07-02. The Company’s cell-free deoxyribonucleic acid (DNA) or (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The firm's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) and Prospera. The firm also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology.
Contact
IPO
Employees
Officers
The intrinsic value of one NTRA stock under the Base Case scenario is 94.61 USD.
Compared to the current market price of 103.71 USD, Natera Inc is Overvalued by 9%.